Revvity, Inc. (RVTY) announced the launch of the in-vitro diagnostic EURORealTime APOE assay in European countries that accept the CE mark on Oct. 2. The assay will likely enable accurate genotyping of the APOE gene. It is worth mentioning that APOE genotyping allows the assessment of a patient's risk for side effects before the start of an anti-amyloid (beta) therapy in Alzheimer's disease (AD). The latest launch in European countries that accept the CE mark is expected to significantly boost Revvity's EUR ...